EDEN PRAIRIE, Minn., Apr 16, 2012 (BUSINESS WIRE) --SurModics IVD Inc., a wholly owned subsidiary of SurModics, Inc. (NASDAQ:SRDX) and a market leader for immunoassay reagents for diagnostic tests used to detect the absence or presence of disease, is pleased to announce the launch of StabilBlot(TM) Blocker Family. The StabilBlot blocker family represents SurModics' newest offering of its Stabil(TM) line of quality, market-proven immunodiagnostic reagent products that enhances sensitivity and minimizes background in blotting applications. The StabilBlot Blocker family was initially highlighted at the February 2012 Molecular Tri-Con IVD conference held in San Francisco, CA.
Membranes used in blotting applications are porous and should be blocked to avoid non-specific binding and background. SurModics' StabilBlot Blocker Family offers a range of product options, both protein-based and synthetic-based, to block non-specific binding as well as enhance sensitivity when used as a blocker and antibody diluent.
SurModics IVD StabilBlot Blocker Family includes:
- StabilBlot Protein Free Blocker
- StabilBlot BSA Blocker
- StabilBlot Casein PBS Blocker
- StabilBlot Casein TBS Blocker (for blocking needs sensitive to phosphates)
- StabilBlot Milk Blocker
A convenient sample pack containing all five formulations is now available to allow users to select the best option based on their specific application requirements. To learn more about SurModics' in vitro diagnostic products, please visit our website (www.surmodics.com), or contact customer service at 952-500-7200 or email@example.com. Easy online ordering is available at http://shop.surmodics.com. StabilBlot is a trademark of SurModics IVD, Inc.
About SurModics, Inc.
SurModics' mission is to exceed our customers' expectations and enhance the well-being of patients by providing the world's foremost, innovative surface modification technologies and in vitro diagnostic chemical components. The Company partners with the world's leading and emerging medical device, diagnostic and life science companies to develop and commercialize innovative products designed to improve patient diagnosis and treatment. Core offerings include surface modification coating technologies that impart lubricity, prohealing, and biocompatibility capabilities; and components for in vitro diagnostic test kits and microarrays. SurModics is headquartered in Eden Prairie, Minnesota. For more information about the Company, visit http://www.surmodics.com. The content of SurModics' website is not part of this release or part of any filings the Company makes with the SEC.
SOURCE: SurModics, Inc.
Tim Arens, 952-500-7000
Vice President Finance and interim Chief Financial Officer